Daily Stock Analysis, APRI, Apricus Biosciences Inc, priceseries

Apricus Biosciences Inc. Daily Stock Analysis
Stock Information
Open
1.07
Close
1.04
High
1.31
Low
0.93
Previous Close
3.19
Daily Price Gain
-2.15
YTD High
3.34
YTD High Date
Feb 15, 2018
YTD Low
0.93
YTD Low Date
Feb 16, 2018
YTD Price Change
-0.98
YTD Gain
-48.51%
52 Week High
3.49
52 Week High Date
Feb 17, 2017
52 Week Low
0.86
52 Week Low Date
May 25, 2017
52 Week Price Change
-2.17
52 Week Gain
-67.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 15. 2017
1.74
Jan 24. 2018
2.44
25 Trading Days
40.32%
Link
Company Information
Stock Symbol
APRI
Exchange
NasdaqCM
Company URL
http://www.apricusbio.com
Company Phone
(858) 222-8041
CEO
Richard W. Pascoe
Headquarters
California
Business Address
11975 EL CAMINO REAL,, SUITE 300, SAN DIEGO,, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001017491
About

Apricus Biosciences, Inc. is a pharmaceutical company focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The company products include Vitaros and Femprox. It operates through Pharmaceutical segment which designs, and develops pharmaceutical products including those with its NexACT platform. Apricus Biosciences was founded in 1987 and is headquartered in San Diego, CA.

Description

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company also engages in developing RayVa, which is in Phase 2 development for the treatment of Raynaud's Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. It operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.